Keith Regnante's most recent trade in Keros Therapeutics Inc was a trade of 44,000 Common Stock done . Disclosure was reported to the exchange on Feb. 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Keros Therapeutics Inc | Keith Regnante | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 44,000 | 44,000 | - | 0 | Common Stock | |
| Keros Therapeutics Inc | Regnante Keith | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 40,000 | 40,000 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Keith Regnante | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 04 Jan 2024 | 40,000 | 40,000 | - | 16 | 640,000 | Common Stock |
| Keros Therapeutics Inc | Keith Regnante | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 45.29 per share. | 04 Jan 2024 | 40,000 | 0 | - | 45.3 | 1,811,600 | Common Stock |
| Keros Therapeutics Inc | Keith Regnante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 04 Nov 2023 | 40,000 | 40,000 | - | 16 | 640,000 | Common Stock |
| Keros Therapeutics Inc | Keith Regnante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2023 | 40,000 | 53,622 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Keith Regnante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 45.29 per share. | 04 Nov 2023 | 40,000 | 0 | - | 45.3 | 1,811,600 | Common Stock |
| Keros Therapeutics Inc | Keith Regnante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 08 Jun 2023 | 20,000 | 20,000 | - | 16 | 320,000 | Common Stock |
| Keros Therapeutics Inc | Keith Regnante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2023 | 20,000 | 93,622 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Keith Regnante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2023 | 20,000 | 113,622 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Keith Regnante | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 08 Jun 2023 | 20,000 | 20,000 | - | 16 | 320,000 | Common Stock |
| Keros Therapeutics Inc | Keith Regnante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 47.66 per share. | 08 Jun 2023 | 17,301 | 2,699 | - | 47.7 | 824,566 | Common Stock |
| Keros Therapeutics Inc | Keith Regnante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 45.03 per share. | 08 Jun 2023 | 15,993 | 4,007 | - | 45.0 | 720,165 | Common Stock |
| Keros Therapeutics Inc | Keith Regnante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 48.65 per share. | 08 Jun 2023 | 2,699 | 0 | - | 48.6 | 131,306 | Common Stock |
| Keros Therapeutics Inc | Keith Regnante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 47.25 per share. | 08 Jun 2023 | 2,579 | 0 | - | 47.3 | 121,858 | Common Stock |
| Keros Therapeutics Inc | Keith Regnante | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 46.46 per share. | 08 Jun 2023 | 1,428 | 2,579 | - | 46.5 | 66,345 | Common Stock |
| Keros Therapeutics Inc | Keith Regnante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 40,000 | 40,000 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Keith Regnante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 50,000 | 50,000 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Keith Regnante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2021 | 49,150 | 49,150 | - | - | Employee Stock Option (right to buy) |